Amgen (AMGN) Cash from Operations (2009 - 2026)

Amgen has reported Cash from Operations for 18 years, with the latest figure at $4.0 billion in Q2 2026.

• On a quarterly basis, Cash from Operations rose 75.53% year-over-year to $4.0 billion in Q2 2026; TTM through Jun 2026 was $12.5 billion, a 3.87% increase from a year earlier, with the FY2025 full-year figure at $10.0 billion, down 13.33% from the prior year.
• Cash from Operations was $4.0 billion for Q2 2026 at Amgen, up from $2.2 billion in the prior quarter.
• The five-year high for Cash from Operations was $4.8 billion in Q4 2024, with the low at $538.0 million in Q4 2023.
• Average Cash from Operations over 5 years is $2.5 billion, with a median of $2.4 billion recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Cash from Operations sank 79.69% in 2023, then surged 786.8% in 2024.
• Over 5 years, Cash from Operations stood at $2.6 billion in 2022, then tumbled by 79.69% to $538.0 million in 2023, then soared by 786.8% to $4.8 billion in 2024, then tumbled by 66.4% to $1.6 billion in 2025, then surged by 149.66% to $4.0 billion in 2026.
• The last three Cash from Operations figures came in at $4.0 billion (Q2 2026), $2.2 billion (Q1 2026), and $1.6 billion (Q4 2025), per Business Quant data.